Home » Topics » BioWorld Science

BioWorld Science
RSS

Neogene licenses portfolio of TCRs targeting KRAS and TP53 mutations from NCI

Jan. 12, 2022

G3PP is a therapeutic target for age-related metabolic diseases

Jan. 12, 2022

ABL and Sanofi enter collaboration and license agreement for ABL-301

Jan. 12, 2022

Dren Bio and Pfizer collaborate to discover and develop bispecific antibodies for cancer

Jan. 12, 2022

VCAM-1-targeting polyelectrolyte complex enhances therapeutic efficacy of miR-92a inhibitors in vivo

Jan. 12, 2022

PostEra and Pfizer expand strategic collaboration

Jan. 12, 2022

REVTx-99 demonstrates in vitro antiviral activity against SARS-CoV-2

Jan. 12, 2022

Methamphetamine harnessed for good in BBB transport

Jan. 12, 2022

CD6-ALCAM pathway is a therapeutic target in SLE

Jan. 12, 2022

Wigen Biomedicine Technology presents new CDK inhibitors

Jan. 12, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...